Potent and selective bivalent inhibitors of BET bromodomains
Michael J. Waring(AstraZeneca (United Kingdom)), Huawei Chen(AstraZeneca (United States)), Alfred A. Rabow(AstraZeneca (United Kingdom)), Graeme E. Walker(AstraZeneca (United Kingdom)), Romel Bobby(AstraZeneca (United Kingdom)), Scott Boiko(AstraZeneca (United States)), Rob H. Bradbury(AstraZeneca (United Kingdom)), Rowena Callis(AstraZeneca (United Kingdom)), Edwin Clark(AstraZeneca (United States)), Ian L. Dale(AstraZeneca (United Kingdom)), Danette L. Daniels(Promega (United States)), Austin Dulak(AstraZeneca (United States)), Liz Flavell(AstraZeneca (United Kingdom)), Geoffrey A. Holdgate(AstraZeneca (United Kingdom)), Thomas A. Jowitt(Wellcome Centre for Cell-Matrix Research), Alexey Kikhney(European Molecular Biology Laboratory), M. McAlister(AstraZeneca (United Kingdom)), Jacqui Méndez(Promega (United States)), D. Ogg(AstraZeneca (United Kingdom)), Joe Patel(AstraZeneca (United States)), Philip Petteruti(AstraZeneca (United States)), Graeme R. Robb(AstraZeneca (United Kingdom)), Matthew B. Robers(Promega (United States)), Sakina Saif(AstraZeneca (United States)), Natalie Stratton(AstraZeneca (United Kingdom)), Dmitri I. Svergun(European Molecular Biology Laboratory), Wenxian Wang(AstraZeneca (United States)), David Whittaker(AstraZeneca (United Kingdom)), David M. Wilson(AstraZeneca (United Kingdom)), Yi Yao(AstraZeneca (United States))
Cited by 135Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis